ReviewAnnals of medicine and surgery (2012)2024
A brief review of current treatment options for osteoarthritis including disease-modifying osteoarthritis drugs (DMOADs) and novel therapeutics.
Review in Annals of medicine and surgery (2012), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Effect of ultrasound-guided genicular nerve neurolysis versus sham procedure on pain in patients with knee osteoarthritis: a randomized clinical trial.Pain medicine (Malden, Mass.) · 2026Trial
- The application of novel ultrathin iron sulphide nanosheets in the nanotherapy of post-traumatic osteoarthritis.Materials today. Bio · 2026Article
- Global Research Trends in Orthobiological Treatments for Osteoarthritis: A Bibliometric Analysis.Healthcare (Basel, Switzerland) · 2026Article
- Overview of the Current Osteoarthritis Treatment in Veterinary Medicine and Future Directions.ACS pharmacology & translational science · 2026Review
- Review
- A disease-severity-responsive nanoparticle enables potent ghrelin messenger RNA therapy in osteoarthritis.Nature nanotechnology · 2026Article
- Microgravity-induced transcriptional reprogramming in embryonic chicken limb bud-derived chondrogenic cultures.Frontiers in cell and developmental biology · 2026Article
- LOXL2 alleviates post-traumatic knee osteoarthritis and pain.Journal of orthopaedic translation · 2025Article
- Knee Osteoarthritis: Current Insights Into Pathophysiology and Non-surgical Management Options.Cureus · 2025Review
- Construction of a comprehensive protein-protein interaction network to identify key genes associated with osteoarthritis.Medicine · 2025Article
- Pharmacist-Driven Chondroprotection in Osteoarthritis: A Multifaceted Approach Using Patient Education, Information Visualization, and Lifestyle Integration.Pharmacy (Basel, Switzerland) · 2025Review
- Unraveling Osteoarthritis: Mechanistic Insights and Emerging Therapies Targeting Pain and Inflammation.Biomolecules · 2025Review
- Inhibitory Effects of Heat-ProcessedInternational journal of molecular sciences · 2025Article
- Observation of the Effects of Infrapatellar Fat Pad Excision on the Inflammatory Progression of Knee Osteoarthritis in Mice.Journal of inflammation research · 2025Article
- Chondroprotective Effect ofInternational journal of molecular sciences · 2024Article
- Comparative Analysis of Osteoarthritis Therapeutics: A Justification for Harnessing Retrospective Strategies via an Inverted Pyramid Model Approach.Biomedicines · 2024Review
- Dehydroepiandrosterone inhibits ADAMTS expression via an ERK-dependent mechanism in chondrocytes.PloS one · 2024Article
- Pharmacological effects and the related mechanism of scutellarin on inflammation-related diseases: a review.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a chronic disorder caused by degenerative changes in articular cartilage, which are mainly manifests as degeneration of cartilage, subchondral bone remodeling, as well as synovial inflammation. Over the next few decades, OA and its burden will continue to increase worldwide, posing a major public health challenge for the foreseeable future. Treatment for OA includes non-pharmacological, pharmacological, and surgical treatments. Existing conservative treatments and joint surgery can only alleviate the symptoms and cannot be cured, so new therapies for OA are urgently needed. Since advances in the understanding of OA pathophysiology, researchers have identified some potential therapeutic targets against degeneration of cartilage, subchondral bone remodeling and synovial inflammation, enabling development of the disease-modifying OA drugs (DMOADs). Additionally, a number of new technologies are also being investigated for treating OA, such as RNA interference (RNAi), CRISPR/Cas9 and PROTAC. The goal of this review is to describe the current development status of DMOADs and to discuss the potential of emerging therapeutic approaches for treating OA, thus providing a reference for OA treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.